Archeon Medical raises €7.5M Series A for its smart ventilator that automates CPR airway management

Archeon Medical (Besançon) has raised €7.5 million in a Series A led by Newfund (via its HEKA health fund), with Eiffel Investment Group, UI Investissement (OSER BFC fund, Bourgogne-Franche-Comté), Majycc Innovation Santé, and Karot Capital participating. The capital targets CE marking and first commercial deployments for EOlife, the company's automated ventilation device for cardiac arrest response.

Founded in 2018 in Besançon — France's medical device cluster in the Bourgogne-Franche-Comté region — Archeon Medical has spent the intervening years developing and refining the device through preclinical and early clinical work. A prior Series A of €5.5M in March 2022 funded that development phase; this second Series A, labelled as such by the investors and French Tech BFC, funds the path to market.

The problem EOlife solves

Out-of-hospital cardiac arrest (OHCA) is one of emergency medicine's most time-sensitive events. Survival hinges on CPR quality — compressions and ventilation started within minutes and maintained without degradation for the duration of the response. Compressions have received significant automation attention (mechanical CPR devices from LUCAS and AutoPulse are well-established). Ventilation has not.

Manual bag-valve-mask ventilation, the standard in the field, is skill-dependent and fatigue-prone. In the controlled environment of an emergency department, the technique is reliable. In the back of a moving ambulance, in a stairwell, or on a street at 03:00, it is not. EOlife replaces the manual bag with an automated ventilation system that maintains target parameters regardless of the physical environment — and monitors the patient in real time, alerting rescuers when ventilation falls outside safe ranges.

Newfund's health bet and the regional ecosystem

Newfund's HEKA health fund leads a round that represents a sharp sector shift from the fund's recent activity. Newfund backed Reecall — a Lyon-based voice AI SaaS — in September 2026; the move to cardiac care hardware covers a different risk profile entirely. The regional investor base — UI Investissement's OSER BFC fund, Majycc Innovation Santé — reflects Besançon's medical device tradition and the Bourgogne-Franche-Comté regional ecosystem's commitment to med-tech.

"EOlife could become the standard of care for out-of-hospital cardiac arrest — this Series A gets us to CE mark and first commercial deployments," the company said.

The CE gate and beyond

The regulatory pathway in Europe for Class IIb medical devices (the likely designation for an active ventilator) runs through a Notified Body audit and clinical evidence review. The €7.5M funds that process — clinical validation studies, the technical file, and the Notified Body engagement — plus the first wave of commercial deployments once approval arrives. European emergency medical services, which procure through national and regional health authorities, are the target buyer. If the CE route succeeds, Archeon enters pre-hospital cardiac care — a market where incumbents have historically moved slowly and clinical need is measurable.